Novel Advances in Cell-Free Therapy for Premature Ovarian Failure (POF): A Comprehensive Review

Premature ovarian failure (POF), is a condition characterized by the early decline of ovulation function. POF is a complex disorder that can be caused by various factors, and the idiopathic form represents a significant proportion of POF patients. Hormone replacement therapy (HRT) is currently consi...

Full description

Saved in:
Bibliographic Details
Published inAdvanced pharmaceutical bulletin Vol. 14; no. 3; pp. 543 - 557
Main Authors Yahyavi, Yahya, Kheradi, Niloufar, Karimi, Abbas, Ebrahimi-Kalan, Abbas, Ramezani, Fatemeh, Yousefi, Soudabe, Teymouri Nobari, Shirin, Sadrekarimi, Hourieh, Nouri, Mohammad, Edalati, Mahdi
Format Journal Article
LanguageEnglish
Published Iran Tabriz University of Medical Sciences 01.10.2024
Subjects
Apoptosis
Autoimmune diseases
Blood platelets
exosome therapy
Females
Fertility
Genetic counseling
Growth factors
Hormone replacement therapy
Iatrogenesis
in vitro activation
Infertility
Medical research
Medicine
MicroRNAs
mitochondrial targeting therapies
Ovaries
Ovulation
plt-exos
prp
Reproductive health
Review
stem cell therapy
Stem cells
Surgery
theca cells signaling pathways
Thyroid gland
Womens health
Exosome therapy
Theca cells signaling pathways
PLT-Exos
In vitro activation
Stem cell therapy
Mitochondrial targeting therapies
PRP
Online AccessGet full text

Cover

More Information
Summary:Premature ovarian failure (POF), is a condition characterized by the early decline of ovulation function. POF is a complex disorder that can be caused by various factors, and the idiopathic form represents a significant proportion of POF patients. Hormone replacement therapy (HRT) is currently considered the first-line treatment for POF. This review aims to provide a comprehensive overview of recent advancements in platelet-rich plasma (PRP), in vitro activation (IVA), stem cell therapy, exosome therapy, microRNAs, and mitochondrial targeting therapies as a promising cell-free therapeutic approach in reproductive medicine. PLT-Exos, a new generation of cells, has been used to treat POF for more than a decade and has been shown to attenuate oocyte morphology and promote the differentiation of theca cells through the upregulation of PI3K/Akt and Bcl2, as well as the downregulation of the Smad and Bax signaling pathways. This review summarizes the current state of the art in the field of PLT-Exos and discusses the advantages and limitations of their potential clinical applications.
Bibliography:SourceType-Scholarly Journals-1
ObjectType-General Information-1
content type line 14
ISSN:2228-5881
2251-7308
DOI:10.34172/apb.2024.059